{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:47:46Z","timestamp":1767142066379,"version":"build-2238731810"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008240","name":"Department of Health of Hebei Province","doi-asserted-by":"publisher","award":["21377765D"],"award-info":[{"award-number":["21377765D"]}],"id":[{"id":"10.13039\/501100008240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["20221440"],"award-info":[{"award-number":["20221440"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11096-022-01504-6","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T05:02:54Z","timestamp":1676610174000},"page":"547-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"45","author":[{"given":"Zhimin","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1543-9000","authenticated-orcid":false,"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"1504_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrcardio.2017.70","volume":"14","author":"A Coats","year":"2017","unstructured":"Coats A, Forman DE, Haykowsky M, et al. Physical function and exercise training in older patients with heart failure. Nat Rev Cardiol. 2017;14:550\u20139.","journal-title":"Nat Rev Cardiol"},{"key":"1504_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/eurheartj\/ehab887","volume":"43","author":"J Bauersachs","year":"2022","unstructured":"Bauersachs J, de Boer RA, Lindenfeld J, et al. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Eur Heart J. 2022;43:367\u201376.","journal-title":"Eur Heart J"},{"key":"1504_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368\u201378.","journal-title":"Nat Rev Cardiol"},{"key":"1504_CR4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jacc.2018.12.072","volume":"73","author":"RS Taylor","year":"2019","unstructured":"Taylor RS, Walker S, Smart NA, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J Am Coll Cardiol. 2019;73:1430\u20133.","journal-title":"J Am Coll Cardiol"},{"key":"1504_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2019.03.530","volume":"74","author":"M Leggio","year":"2019","unstructured":"Leggio M, Tiberti C, Armeni M, et al. Exercise capacity characterization and physical activity intensification should be priorities in heart failure patients. J Am Coll Cardiol. 2019;74:589\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"1504_CR6","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1161\/CIR.0000000000000767","volume":"141","author":"C White-Williams","year":"2020","unstructured":"White-Williams C, Rossi LP, Bittner VA, et al. Addressing social determinants of health in the care of patients with heart failure: a scientific statement from the american heart association. Circulation. 2020;141:e841\u201363.","journal-title":"Circulation"},{"key":"1504_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","volume":"143","author":"I Johansson","year":"2021","unstructured":"Johansson I, Joseph P, Balasubramanian K, et al. Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23000 patients from 40 countries. Circulation. 2021;143:2129\u201342.","journal-title":"Circulation"},{"key":"1504_CR8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","volume":"128","author":"VL Roger","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128:1421\u201334.","journal-title":"Circ Res"},{"key":"1504_CR9","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018;137:1450\u20139.","journal-title":"Circulation"},{"key":"1504_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19:98.","journal-title":"Cardiovasc Diabetol"},{"key":"1504_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/ejhf.2135","volume":"23","author":"K Bhatia","year":"2021","unstructured":"Bhatia K, Jain V, Gupta K, et al. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk. Eur J Heart Fail. 2021;23:1002\u20138.","journal-title":"Eur J Heart Fail"},{"key":"1504_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40265-021-01538-6","volume":"81","author":"M Evans","year":"2021","unstructured":"Evans M, Morgan AR, Yousef Z, et al. Optimising the heart failure treatment pathway: the role of SGLT2 inhibitors. Drugs. 2021;81:1243\u201355.","journal-title":"Drugs"},{"key":"1504_CR13","doi-asserted-by":"publisher","first-page":"636152","DOI":"10.3389\/fcvm.2021.636152","volume":"8","author":"Q Zeng","year":"2021","unstructured":"Zeng Q, Zhou Q, Liu W, et al. Mechanisms and perspectives of sodium-glucose co-transporter 2 inhibitors in heart failure. Front Cardiovasc Med. 2021;8:636152.","journal-title":"Front Cardiovasc Med"},{"key":"1504_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial. Circulation. 2020;141:90\u20139.","journal-title":"Circulation"},{"key":"1504_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/eurheartj\/ehab057","volume":"42","author":"JA Spertus","year":"2021","unstructured":"Spertus JA. Quality of life in EMPEROR-reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care. Eur Heart J. 2021;42:1213\u20135.","journal-title":"Eur Heart J"},{"key":"1504_CR16","first-page":"1539","volume":"327","author":"A Slomski","year":"2022","unstructured":"Slomski A. Empagliflozin improves quality of life in HFpEF. JAMA. 2022;327:1539.","journal-title":"JAMA"},{"key":"1504_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ejhf.2397","volume":"24","author":"D Tomasoni","year":"2022","unstructured":"Tomasoni D, Fonarow GC, Adamo M, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2022;24:431\u201341.","journal-title":"Eur J Heart Fail"},{"key":"1504_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijcard.2021.10.008","volume":"345","author":"Z He","year":"2021","unstructured":"He Z, Yang L, Nie Y, et al. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2021;345:83\u20138.","journal-title":"Int J Cardiol"},{"key":"1504_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420\u20138.","journal-title":"Diabetes Care"},{"key":"1504_CR20","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954\u201360.","journal-title":"Nat Med"},{"key":"1504_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143:298\u2013309.","journal-title":"Circulation"},{"key":"1504_CR22","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143:1673\u201386.","journal-title":"Circulation"},{"key":"1504_CR23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1504_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1504_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1504_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1504_CR27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463\u201376.","journal-title":"Circulation"},{"key":"1504_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","volume":"228","author":"J Jensen","year":"2020","unstructured":"Jensen J, Omar M, Kistorp C, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020;228:47\u201356.","journal-title":"Am Heart J"},{"issue":"3","key":"1504_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena JA, et al. Randomized trial of empagliflozin in non-diabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"1504_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"M Lee","year":"2021","unstructured":"Lee M, Brooksbank K, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143:516\u201325.","journal-title":"Circulation"},{"key":"1504_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28:809\u201313.","journal-title":"Nat Med"},{"issue":"2","key":"1504_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"1504_CR33","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"14","key":"1504_CR34","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368.","journal-title":"JAMA"},{"issue":"4","key":"1504_CR35","first-page":"383","volume":"8","author":"A Yousif","year":"2021","unstructured":"Yousif A, Madhavan MV, Stone GW, et al. Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. Eur Heart J Qual Care Clin Outcomes. 2021;8(4):383\u201390.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"5","key":"1504_CR36","first-page":"495","volume":"25","author":"UM Shariq","year":"2020","unstructured":"Shariq UM, Jamal ST, Mustafa MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2020;25(5):495\u2013502.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"1504_CR37","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-021-01565-6","volume":"27","author":"S Fu","year":"2021","unstructured":"Fu S, Litwin SE, Tedford RJ. Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies. Nat Med. 2021;27(11):1872\u20133.","journal-title":"Nat Med"},{"issue":"12","key":"1504_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1504_CR39","first-page":"83","volume":"20","author":"C Zheng","year":"2021","unstructured":"Zheng C, Lin M, Chen Y, et al. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. BioMed Central. 2021;20(1):83.","journal-title":"BioMed Central"},{"issue":"10","key":"1504_CR40","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1111\/dom.14092","volume":"22","author":"W Wang","year":"2020","unstructured":"Wang W, Zhang L, Pei X, et al. Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(10):1767\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1504_CR41","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacc.2021.02.005","volume":"77","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Vaduganathan M. SGLT-2 inhibitors in heart failure: volume or value? J Am Coll Cardiol. 2021;77(11):1393\u20136.","journal-title":"J Am Coll Cardiol"}],"updated-by":[{"DOI":"10.1007\/s11096-023-01572-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000}}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01504-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T08:11:11Z","timestamp":1686211871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01504-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01504-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11096-023-01572-2","URL":"https:\/\/doi.org\/10.1007\/s11096-023-01572-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}